Research and Development

Shaping the future of non-invasive diagnostics with artificial intelligence.

Strong Scientific Expertise

Widely used, researched and validated patented test

285
Studies published
By
1133
Authors
In
89
Journals

fibronostics US studies

Title

EVALUATING SERUM BIOMARKERS LIVERFAST SURROGATES OF LIVER FIBROSIS AND STEATOSIS COULD IDENTIFY RISKS IN A CLINICAL POPULATION EXPERIENCING SARS-COV2 INFECTION (COVID).

Lead Author

Dr. Maryna Raskin

Study Population

Miscellaneous n=10,623
LIVERFASt™ & LIVERFASt Select

Conclusion

LIVERFASt™ Steatosis and Fibrosis scores are NITs that could be used to screen populations at risk of MetS and liver disease to identify those at risk of COVID-19.

Location

Health Catalyst US

fibronostics US studies

Title

SIMULATING CLINICAL CONFIDENCE INTERVALS FOR BLACK-BOX ALGORITHMIC PREDICTIONS OF LIVER STEATOSIS.

Lead Author

Dr. Brian Cohn

Study Population

IT simulations
10,000 replicates per biomarker

Conclusion

Noise injection allows for nuanced tailoring & interpretation of results inferred by an AIA. We equip clinicians with an interactive tool to contextualize therapeutic expectations & aid in patient education towards adherence endpoints.
In effect, providing a new, nuanced view of how AIA assess LD.

Location

Fibronostics US

fibronostics US studies

Title

MACHINE LEARNING TECHNOLOGY FOR EVALUATION OF LIVER FIBROSIS, INFLAMMATION ACTIVITY AND STEATOSIS (LIVERFASt™).

Lead Author

Abhishek Aravind

Study Population

NAFL to advanced NASH n=2862
LIVERFASt™

Conclusion

The modified SAF scoring system generated by LIVERFASt™ provided a simple & convenient diagnosis of NAFLD & NASH, and staging of the three liver lesions as shown in a cohort of SEA.

Location

Fibronostics Singapore

fibronostics US studies

Title

PREDICTIVE VALUE OF NON-INVASIVE METHODS LIVERFAST, ACOUSTIC RADIATION FORCE IMPULSE (ARFI), FIB-4 & APRI TO IDENTIFY THE NATURAL PHASES OF CHB INFECTION FROM NUH CHB STUDY COHORT OF SINGAPORE.

Lead Author

Prof. Lim Seng Gee

Study Population

CHB n=724, LIVERFASt™

Conclusion

LF-Fibrosis & LF-Activity are reliable tools for screening HBV infected patients & for detecting phase-related liver disease, with better NPV than APRI or FIB-4. Management of HBV pts could be improved by LF tests.

Location

National University Health System (NUHS) Singapore

fibronostics US studies

Title

COMPARATIVE ASSESSMENT LIVER LESIONS USING NON-INVASIVE SERUM BIOMARKERS LIVERFASt™, FIB4, APRI AND LIVER STIFFNESS MEASUREMENT (LSM, FIBROSCAN) IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH LIVER BIOPSY.

Lead Author

Prof. Wattana

Study Population

CHC n=100, LIVERFASt™ & Biopsy

Conclusion

Fibrosis Activity
LIVERFASt™ 0.806 0.700
TE 0.810 NA
FIB4 0.754 NA
APRI 0.796 NA

Srinagarind Hospital, Khon Kaen University Thailand

fibronostics US studies

Title

COMPARATIVE PERFORMANCES OF LIVERFAST, VTCE (FIBROSCAN) & OTHER SERUM NITs FOR THE DIAGNOSIS OF ADVANCED CLD IN NAFLD PATIENTS FROM A COHORT WITH LIVER BIOPSY.

Lead Author

Prof. Victor De Ledinghen

Study Population

NAFLD n=583, LIVERFAStTM & Biopsy

Conclusion

LIVERFASt™ – Fibrosis is a NIT for the diagnosis of advanced disease in NAFLD patients either in T2DM or non-T2DM pts. This score could be very useful to select patients for CT & as screening test in general population.

Non-T2DM (n=287) 0.827
T2DM (n=301) 0.788

Location

University Hospital Center (CHU), Bordeaux France

To learn more about integrating our products in your organization.